ReviewDrugs & aging2016
Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Review in Drugs & aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Neuropsychiatric symptoms and their impact on cognitive functioning in patients with parkinson's disease: A systematic review of the literature.Cognitive, affective & behavioral neuroscience · 2026Pooled it
- Cognitive Outcomes of Advanced Therapies in Parkinson's Disease: A Systematic Review of Apomorphine and Levodopa-Carbidopa Intestinal Gel Therapies.European journal of neurology · 2025Pooled it
- Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2024Guideline
- Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson's Symptoms.International journal of environmental research and public health · 2021Pooled it
- Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward.NeuroSci · 2026Review
- Psychotropic medication use among community dwellers with and without Parkinson's disease - A nationwide cohort study.British journal of clinical pharmacology · 2026Article
- Psychotic Symptoms Following Subthalamic DBS in Parkinson's Disease: Three Clinical Cases and Literature Review.Clinical case reports · 2026Article
- Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Insights From a Real-World Cohort.Journal of movement disorders · 2026Article
- Treatment of Parkinson's Disease-Related Psychosis.Clinical pharmacology : advances and applications · 2026Review
- A systematic review of the clinical correlates of delusions in Parkinson's disease.Clinical parkinsonism & related disorders · 2026Review
- Antipsychotics for Parkinson's disease: a protocol for a systematic review with network meta-analysis and trial sequential analysis.BMJ open · 2025Article
- Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics-a two-decade real-world pharmacovigilance analysis based on the FAERS database.The international journal of neuropsychopharmacology · 2025Article
- Combined Pimavanserin and Maintenance Electroconvulsive Therapy: A Novel Approach to Parkinson's Disease Psychosis.Cureus · 2024Article
- Article
- Case Files of the Emory University Medical Toxicology Fellowship: A Patient Presents to the Outpatient Toxicology Clinic with Delusions of Being Poisoned.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinson's Disease: A Basic and Clinical Approach.Brain sciences · 2023Review
- Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease.Parkinson's disease · 2023Article
- Increased Serum S100β Concentration is Associated with Depression in Parkinson's Disease.Neuropsychiatric disease and treatment · 2023Article
- Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions.Neuropsychiatric disease and treatment · 2023Review
- High risk of developing dementia in Parkinson's disease: a Swedish registry-based study.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine. Of these, clozapine is effective but is associated with a poor side-effect profile and the necessity for frequent blood draws. Clinicians prefer quetiapine for its theoretically better safety profile, although there is no evidence for efficacy in treating psychosis. All atypical antipsychotics are associated with increased mortality in this patient population. Cholinesterase inhibitors can ameliorate psychosis symptoms. The serotonin 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.